Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence

Program Goals

Insulin Deficiency and Glucagon Hypersecretion in T2D

Postprandial Glucagon Is Excessive and Not Corrected by Exogenous Insulin

Incretin Hormome Physiology

Signal Transduction and GLP-1

Summary of Main GLP-1 Effects

2012 ADA/EASD Position Statement

Impact of Exenatide Twice-Daily Therapy Over 3 Years: Effect on HbA1c and Body Weight

Considerations in Choosing a GLP-1 Receptor Agonist

EXN Once Weekly vs Sitagliptin and Pioglitazone: HbA1c Reduction

Nausea With GLP-1 Receptor Agonists Tends to Decrease With Time

Strategies to Minimize the Occurrence of Nausea

Minor Hypoglycemia* With GLP-1 Receptor Agonists

Liraglutide/Exenatide: Black Box Warning Risk of Thyroid C-Cell Tumors

Incretin-based Therapies: Concern About Acute Pancreatitis

Sitagliptin and Exenatide Associated With Increased Risk for Hospitalization for Acute Pancreatitis

Incretin-based Therapies: Renal Impairment

Incretin-based Therapies Associated With Increased Alpha-Cell Hyperplasia

Exenatide Twice Daily Added to Insulin Glargine

Closing Comments

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)